• The Benefits and Risks of Antinarcoleptic Medications

HOME > Anti Narcoleptic Articles > Armodafinil promotes wakefulness

Jun 21 / 2021

Armodafinil promotes wakefulness

Armodafinil (which is also famous under the name Nuvigil) is a drug that is used to promote wakefulness.

It is a new legal stimulant, taken by athletes to promote reduction of excess weight, to treat chronic fatigue syndrome, and with the purpose to make better macrobiotic level and stamina, depression, schizophrenia, cerebral palsy, multiple sclerosis, Parkinson's disease and fibromyalgia.   This medication has been approved in the US since 2007 and actually is a derivative of a Modafinil.

This drug has several similar effects, but unlike the latter, patients have noticed a slightly higher potency level. It also provides a better stimulant effect and lasts much longer. Armodafinil has been recognized as an effective medication by the FDA and is highly recommended in treatment of shift work sleep disorder and narcolepsy. The drug can also be taken in cases of treatment of obstructive sleep apnea as an adjunctive drug.

Dosage of Generic Armodafinil.

For treatment of obstructive sleep apnea and narcolepsy, Nuvigil is to be taken one time a day (the dose is 150 mg), or 250 mg dose in the morning. In case with shift work sleep disorder, 150 mg must be taken one hour before starting work.

Side effects of the drug.

Some side effects of the given drug might include headache, insomnia, lack of appetite, sometimes dizziness and high blood pressure. It is not always necessary that you might have any of the mentioned side effects. But if you feel bad when taking this medication, you should consult your doctor. However, remember, that as your body adjusts to the drug during the process of treatment, you might not need any medical attention at all.

Is it possible to treat depression in people with bipolar disorder by Armodafinil?

Armodafinil has been successfully tested as the treatment of depression for people with bipolar disorder. The scientists have compared for 8 weeks the efficiency and safety of the given drug (150 mg daily) and placebo as a companion product to a mood stabilizer. In the test took part two hundred and fifty seven patients who have bipolar disorder in the phase of depression.

Successes of the patients taking Nuvigil were measured on a primary scale with 30 depressive symptoms (IDS-C30). The manifestations of mental disorders were declined by several points.   Armodafinil has a positive impact on the patients. Such levels as mania, depression and suicidal tendencies were compared between groups of the drug and placebo. Among patients who were treated with placebo, two quite serious cases of mania were observed. They were also increasingly vulnerable to anxiety and hyperactivity.